OncoVerity - About the company
OncoVerity is a series A company based in Aurora (United States), founded in 2022. It operates as a Developer of therapeutics for the treatment of cancer. OncoVerity has raised $14M in funding from argenx and RefinedScience. The company has 100 active competitors, including 32 funded and 22 that have exited. Its top competitors include companies like Ossium Health, Rigel and Ajax.
Company Details
Developer of therapeutics for the treatment of cancer. The company is pioneering the use of clinical and single cell multiomics database to advance the development of cusatuzumab, a novel anti-CD70 antibody, for the treatment of acute myeloid leukemia (AML) and other cancers.
Key Metrics
Founded Year
2022
Location
Aurora, United States
Stage
Series A
Total Funding
$14M in 1 round
Latest Funding Round
Ranked
45th among 100 active competitors
Employee Count
9 as on Sep 30, 2026
Similar Companies
Legal entities associated with OncoVerity
OncoVerity is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
OncoVerity, Inc. CIN: 20228281916 , United States, Deadpooled | Dec 29, 2022 | - | - | - |
Sign up to download OncoVerity's company profile
OncoVerity's funding and investors
OncoVerity has raised a total funding of $14M over 1 round. Its latest funding round was a Series A round on Nov 22, 2024 for $*****. 2 investors participated in its latest round. OncoVerity has 2 institutional investors.
Here is the list of recent funding rounds of OncoVerity:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 22, 2024 | 8051850 | Series A | 1416091 | 7240022 | 1172364 | 5949976 |
Access funding benchmarks and valuations. Sign up today!View details of OncoVerity's funding rounds and investors
OncoVerity's founders and board of directors
Founder? Claim ProfileOncoVerity's employee count trend
OncoVerity has 9 employees as of Sep 26. Here is OncoVerity's employee count trend over the years:
Uncover OncoVerity's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
OncoVerity's Competitors and alternates
Top competitors of OncoVerity include Ossium Health, Rigel and Ajax. Here is the list of Top 10 competitors of OncoVerity, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Ossium Health 2016, San Francisco (United States), Series C | Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning | $125M | 65/100 | |
2nd | Rigel 1996, San Francisco (United States), Public | Developer of drugs for hematologic disorders, cancer, and rare immune disease | - | 64/100 | |
3rd | Ajax 2019, Cambridge (United States), Acquired | Developer of targeted therapies for the treatment of hematologic malignancies | $135M | 63/100 | |
4th | Sierra Oncology 2003, Vancouver (Canada), Acquired | Developer of targeted therapies to treat cancer | $75M | 63/100 | |
5th | Orca Bio 2016, Menlo Park (United States), Series F | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | $300M | 63/100 | |
6th | MaaT Pharma 2014, Lyon (France), Public | Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases | $42.3M | 61/100 | |
7th |  Adicet Bio 2014, Menlo Park (United States), Public | Developer of immune cell therapeutic solutions for the treatment of cancer | $51M | 61/100 | |
8th | StemlineTherapeutics 2003, New York City (United States), Acquired | Oncology therapeutics innovator focused on transforming cancer patient lives | $15.1M | 58/100 | |
9th | _1559116612173.png?devicePixelRatio=2&height=30&width=30){kind=logo} CERo Therapeutics 2016, San Francisco (United States), Public | Developer of platforms for cellular immunotherapy | $54.8M | 58/100 | |
10th |  Curocell 2016, Yuseong District (South Korea), Series D | Developer of immune cell therapies | $82.4M | 56/100 | |
45th |  OncoVerity 2022, Aurora (United States), Series A | Developer of therapeutics for the treatment of cancer | $14M | 37/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on OncoVerity's competitors? Click here to see the top ones
OncoVerity's Investments and acquisitions
OncoVerity has made no investments or acquisitions yet.
Reports related to OncoVerity
Here is the latest report on OncoVerity's sector:
News related to OncoVerity
•
•
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AMLBusiness Wire•Nov 22, 2024•OncoVerity, argenx, RefinedScience
•
OncoVerity, Inc. Announces Exclusive Worldwide Licensing Rights to Cusatuzumab and Appoints Max Colao as Chief Executive OfficerTullahoma News•Mar 28, 2023•OncoVerity
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about OncoVerity
Explore our recently published companies
- Heatwise - New York City based, Unfunded company
- Decode Greatness - Regina based, 2015 founded, Unfunded company
- Avocado Software - Unfunded company
- Ultimate Oil & Gas - United Arab Emirates based, 2016 founded, Unfunded company
- Haralago - Unfunded company
- Grace Group - Delhi based, 1987 founded, Unfunded company
